Arimidex (anastrozole) [summary of product characteristics]. HPRA.

Regulatory approval published by the Health Products Regulatory Authority.

Citation

Laboratoires Juvise Pharmaceuticals. Arimidex 1mg Film-coated Tablets (Anastrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf. Revised June 2021. Accessed May 25, 2025.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.	3
Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.	3
Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole